Falang Database driver not enabled

Tissium closes a massive 39M€ Series B funding round

Tissium is a life sciences company developing fully synthetic, biomophic programmable polymers. The company just rasied 38,75M€ in a Series B funding round. The funding will mainly be used to support the global expansion of the company’s platform of polymers across a variety of theapeutic fields, including nerve repair, cardiovascular and gastroenterology.